View More Recent Stories
-
Bristol-Myers Squibb (BMY) Announces U.S. FDA Accelerated Approval of KRAZATI in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic
-
Bristol-Myers Squibb (BMY) Receives EMA Validation of Application for Subcutaneous Nivolumab
-
Bristol-Myers Squibb (BMY) Appoints Michael R. McMullen to its Board
-
Bristol-Myers Squibb (BMY) Declares $0.60 Quarterly Dividend; 5.9% Yield
-
Bristol-Myers Squibb (BMY) Announces FDA Granted Accelerated Approval of Augtyro
-
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
-
Democratic lawmaker presses antitrust enforcers on company ties, settlements
